CPT Codes

Myriad Brand CPT Code
EndoPredict® Breast Cancer 81522
Prolaris® Prostate Cancer 81541
Vectra® Rheumatoid Arthritis 81490
myChoice® CDx FDA-Approved Targeted Therapies 0172U
myPath® Melanoma 0090U

Medicare Coverage by Brand

  • Medicare Coverage

    “Medicare […] will provide limited coverage for the EndoPredict breast cancer gene expression test for the management of post-menopausal women diagnosed with early-stage (TNM stage T1-3, N0-1) estrogen-receptor (ER) positive, Her2-negative breast cancer, who are either lymph node-negative or who have 1-3 positive nodes, and for whom treatment with adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitors) is being considered.”

    MolDX: EndoPredict Breast Cancer Gene Expression Test (37311), effective date 1/30/2018.

    Register to Download PDF

  • Favorable technical assessment by MolDX in October 2014

    Local Coverage Determination (LCD): MolDX: GeneSight Assay for Refractory Testing (L35443)

    Register to View

  • Medicare Coverage

    “This Medicare contractor will provide limited coverage for the myPath Melanoma assay for the diagnosis or exclusion of melanoma from a biopsy…”

    MolDX: myPath Melanoma Assay (L37881), effective date 4/29/2019

    Register to Download PDF

  • Covered by Medicare

    Prolaris® Prostate Cancer Genomic Assay

    • L36350: LCD for NCCN very low- and low-risk
    • L37082: LCD for NCCN favorable intermediate-risk

    Register to Download PDFs

Laboratory Accreditations

From state licenses to ISO Accreditation, Myriad has several clinical laboratory certifications. You can find them here:

View Lab Accreditations